20
Participants
Start Date
June 7, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2027
Psilocybin
The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.
Trauma-focused psychotherapy
Components of trauma-focused psychotherapy will include Cognitive Processing Therapy and in vivo exposure. Such components of evidence-based psychotherapy may lower the safety risk profile for this vulnerable population and enhance the effect size and maintenance of psilocybin therapy.
Standard psychological support
Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.
RECRUITING
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore
Steven & Alexandra Cohen Foundation
OTHER
Usona Institute
OTHER
Johns Hopkins University
OTHER